EUVIMEDEUVIMED entdecken
Open Access

Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)

Rohan Kalyan Rej iD, Biao Hu iD, Zhixiang Chen iD, Ranjan Kumar Acharyya iD, Dimin Wu, Hoda Metwally, Donna McEachern, Yu Wang, Wei Jiang, Longchuan Bai, Leticia S Nishimura, Christina L Gersch und 12 weitere

Journal of Medicinal Chemistry · 12.12.2024 · 67 (23) · 20933-20965

DOI: 10.1021/acs.jmedchem.4c01401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 25.11.2024. Verfasst von Rohan Kalyan Rej und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor 48109, United States. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Breast Cancer Research Foundation, Center for Scientific Review.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibition of estrogen receptor alpha (ERα) signaling is an established therapeutic approach for the treatment of ER-positive (ER+) breast cancers, but new therapeutic strategies are urgently needed to overcome clinical resistance. In the present study, we describe the discovery and extensive evaluation of ERD-12310A as an exceptionally potent and orally efficacious PROTAC degrader of ERα. ERD-12310A achieved a DC50 value of 47 pM and is 10 times more potent than ARV-471. ERD-12310A displayed an improved pharmacokinetic profile in mice and rats over ARV-471. ERD-12310A attained tumor regression in the ER+, estrogen-dependent MCF-7 breast cancer xenograft model with wild-type ER and is more potent than ARV-471. Importantly, ERD-12310A achieved strong tumor growth inhibition in MCF-7 xenograft tumors harboring the clinically relevant ESR1Y537S mutation, which confers resistance to traditional antiestrogens. Our data position ERD-12310A as a promising candidate for further development as a potential therapy for ER+ breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaBreast NeoplasmsHumansAnimalsFemaleMiceRatsAdministration, OralMCF-7 CellsAntineoplastic AgentsXenograft Model Antitumor AssaysStructure-Activity RelationshipMice, NudeDrug DiscoveryRats, Sprague-DawleyCell Proliferation

Substanzen

Estrogen Receptor alphaAntineoplastic AgentsESR1 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor 48109, United States.
  • Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor 48109, United States.
  • Rogel Cancer Center, University of Michigan, Ann Arbor 48109, United States.
  • Department of Chemistry, University of Illinois, 600 South Mathews Avenue, Urbana 61801, United States.
  • SK Life Science Laboratories, 2500 Renaissance Boulevard, King of Prussia 09406, United States.
  • Department of Pharmacology, University of Michigan, Ann Arbor 48109, United States.

ORCID-Profile: Rohan Kalyan Rej, Biao Hu, Zhixiang Chen, Ranjan Kumar Acharyya, Duxin Sun, John A Katzenellenbogen, Wenxue Wu, E Scott Priestley, Shaomeng Wang

Förderung

  • NCI NIH HHS
  • Breast Cancer Research Foundation
  • Center for Scientific Review
  • Oncopia Therapeutics, Inc.
  • Proteovant Therapeutics, Inc.

Zitieren

APA

Rej, R. K., Hu, B., Chen, Z., Acharyya, R. K., Wu, D., Metwally, H., McEachern, D., Wang, Y., Jiang, W., Bai, L., Nishimura, L. S., Gersch, C. L., Wang, M., Wen, B., Sun, D., Carlson, K., Katzenellenbogen, J. A., Xu, G., Zhang, W., …, & Wang, S. (2024). Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα). Journal of Medicinal Chemistry, 67(23), 20933-20965. https://doi.org/10.1021/acs.jmedchem.4c01401

Vancouver

Rej RK, Hu B, Chen Z, Acharyya RK, Wu D, Metwally H, et al. Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα). Journal of Medicinal Chemistry. 2024;67(23):20933-20965. doi:10.1021/acs.jmedchem.4c01401

BibTeX
@article{Rej2024,
  author = {Rej, Rohan Kalyan and Hu, Biao and Chen, Zhixiang and Acharyya, Ranjan Kumar and Wu, Dimin and Metwally, Hoda and McEachern, Donna and Wang, Yu and Jiang, Wei and Bai, Longchuan and Nishimura, Leticia S and Gersch, Christina L and Wang, Meilin and Wen, Bo and Sun, Duxin and Carlson, Kathryn and Katzenellenbogen, John A and Xu, Guozhang and Zhang, Weihong and Wu, Wenxue and Priestley, E Scott and Sui, Zhihua and Rae, James M and Wang, Shaomeng},
  title = {Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {23},
  pages = {20933--20965},
  doi = {10.1021/acs.jmedchem.4c01401}
}
Kostenlos starten →